郭舒杨;郭胜楠;白玉;

• 1:国家药品监督管理局药品审评中心

摘要(Abstract)：

百白破联合疫苗的应用对预防百日咳、白喉、破伤风起到非常重要的作用。但自上个世纪80年代开始,世界各地普遍出现"百日咳重现"现象,百日咳发病率逐年升高,而成年人感染百日咳并传染婴幼儿成为重要的传播方式。WHO建议成年人接种破伤风类毒素、降低抗原含量的白喉毒素和无细胞百日咳联合疫苗(tetanus toxoid,reduced diphtheria toxoid,and acellular pertussis,Tdap)以预防百日咳。本文对部分Tdap的临床研究及其应用情况作一综述。

关键词(KeyWords)： 破伤风;白喉;百日咳;联合疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 郭舒杨;郭胜楠;白玉;

DOI: 10.13200/j.cnki.cjb.002730

参考文献(References)：

• [1]MARTI M.Pertussis vaccines:WHO position paper,August2015-Recommendations[J].Vaccine,2016,34(12):1423-1425.
• [2]CHERRY J,BRUNNEL P,GOLDEN G.Report of the task force on pertussis and pertussis immunization-1988.Pediatrics,1988,81(6):939-984.
• [3]WALSH J,WARREN K.Selective primary health care:an interim strategy for disease control in developing countries[J].Social Sci&Med Economics,1980,14(2):145-163.
• [4]WHO.Tetanus vaccines:WHO position paper-February 2017[J].Releve Epidemiologique Hebdomadaire,2017,92(6):53-76.
• [5]KYU H,MUMFORD J,STANAWAY J D,et al.Mortality from tetanus between 1990 and 2015:findings from the global burden of disease study 2015[J].BMC Public Health,2017,17(1):179.
• [6]CROWCROFT N,BOOY R,HARRISON T,et al.Severe and unrecognised:pertussis in UK infants[J].Arch Dis Childhood,2003,88(9):802-806.
• [7]SALIM A.Pertussis-United States,2001-2003[J].Mmwr Morb Mortal Wkly Rep,2005,54(50):1283-1286.
• [8]Pamphlet(or booklet).2014 provisional pertussis surveillance report.2015.https://stacks.cdc.gov/view/cdc/31305/cdc_31305_DS1.pdf.
• [9]LIANG J,TIWARI T,MORO P,et al.Prevention of pertussis,tetanus,and diphtheria with vaccines in the United States:recommendations of the Advisory Committee on Immunization Practices(ACIP)[J].MMWR Recommend Rep,2018,67(2):1-44.
• [10]FORSYTH K,WIRSING VON KONIG C H,TAN T,et al.Prevention of pertussis:recommendations derived from the second Global Pertussis Initiative roundtable meeting[J].Vaccine,2007,25(14):2634-2642.
• [11]THIERRY-CARSTENSEN B,JORDAN K,UHLVING H,et al.A randomised,double-blind,non-inferiority clinical trial on the safety and immunogenicity of a tetanus,diphtheria and monocomponent acellular pertussis(TdaP)vaccine in compa-rison to a tetanus and diphtheria(Td)vaccine when given as booster vaccinations to healthy adults[J].Vaccine,2012,30(37):5464-5471.
• [12]HAN S,KANG K,HUH D,et al.Preliminary study on the immunogenicity of a newly developed GCC Tdap vaccine and its protection efficacy against Bordetella pertussis in a murine intranasal challenge model[J].Clin Exp Vaccin Res,2015,4(1):75-82.
• [13]SIRIVICHAYAKUL C,CHANTHAVANICH P,LIMKITTIKULK,et al.Safety and immunogenicity of a combined tetanus,diphtheria,recombinant acellular pertussis vaccine(TdaP)in healthy Thai adults[J].Hum Vaccin Immunother,2017,13(1):136-143.
• [14]SRICHAROENCHAI S,SIRIVICHAYAKUL C,CHOKEPHAI-BULKIT K,et al.A genetically inactivated two-component acellular pertussis vaccine,alone or combined with tetanus and reduced-dose diphtheria vaccines,in adolescents:a phase 2/3,randomised controlled non-inferiority trial[J].Lancet Infect Dis,2018,18(1):58-67.
• [15]EDWARDS K,DECKER M.Pertussis vaccines//Vaccine[M].6th ed.Amsterdam:Elsevier Saunders,2012:447-492.
• [16]PICHICHERO M,BLATTER M,KENNEDY W,et al.Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents[J].Pediatrics,2006,117(4):1084-1093.
• [17]BLATTER M,FRIEDLAND L,WESTON W,et al.Immunogenicity and safety of a tetanus toxoid,reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults19-64 years of age[J].Vaccine,2009,27(5):765-772.
• [18]WESTON W,FRIEDLAND L,WU X,et al.Vaccination of adults 65 years of age and older with tetanus toxoid,reduced diphtheria toxoid and acellular pertussis vaccine(Boostrix((R))):results of two randomized trials[J].Vaccine,2012,30(9):1721-1728.
• [19]WARD J,CHERRY J,CHANG S,et al.Efficacy of an acellular pertussis vaccine among adolescents and adults[J].NEngl J Med,2005,353(15):1555-1563.
• [20]SOUTHERN J,ANDREWS N,BURRAGE M,et al.Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UKteenagers[J].Vaccine,2005,23(29):3829-3835.
• [21]KNUF M,ZEPP F,MEYER C,et al.Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population[J].Vaccine,2006,24(12):2043-2048.
• [22]TRAN MINH N N,HE Q,RAMALLHO A,et al.Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents[J].Pediatrics,1999,104(6):e70.
• [23]THEETEN H,VAN DAMME P,HOPPENBROUWERS K,et al.Effects of lowering the aluminium content of a dTpa vaccine on its immunogenicity and reactogenicity when given as a booster to adolescents[J].Vaccine,2005,23(12):1515-1521.
• [24]KOVAC M,KOSTANYAN L,MESAROS N,et al.Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence:An open,phase III,non-randomized,multi-center study[J].Hum Vaccin Immunother,2018,14(8):1977-1986.
• [25]ZEPP F,KNUF M,HABERMEHL P,et al.Safety of reducedantigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussiscontaining vaccine[J].J Pediatr,2006,149(5):603-610.
• [26]ARGUEDAS A,SOLEY C,LOAIZA C,et al.Safety and immunogenicity of one dose of MenACWY-CRM,an investiga-tional quadrivalent meningococcal glycoconjugate vaccine,when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines[J].Vaccine,2010,28(18):3171-3179.
• [27]WHEELER C,HARVEY B,PICHICHERO M,et al.Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid,reduced diphtheria toxoid,and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age:results from a randomized open trial[J].Pediatr Infect Dis J,2011,30(12):e225-234.
• [28]COLLINS C,SALT P,MCCARTHY N,et al.Immunogenicity and safety of a low-dose diphtheria,tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children[J].Vaccine,2004,22(31-32):4262-4269.
• [29]LANGLEY J,PREDY G,GUASPARINI R,et al.An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine[J].Vaccine,2007,25(6):1121-1125.
• [30]PICHICHERO M,RENNELS M,EDWARDS K,et al.Combined tetanus,diphtheria,and 5-component pertussis vaccine for use in adolescents and adults[J].JAMA,2005,293(24):3003-3011.
• [31]HALPERIN S,SMITH B,RUSSELL M,et al.An adult formulation of a five-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids is safe and immunogenic in adolescents and adults[J].Vaccine,2000,18(14):1312-1319.
• [32]HALPERIN S,SMITH B,RUSSELL M,et al.Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults[J].Pediatr Infect Dis J,2000,19(4):276-283.
• [33]VESIKARI T,VAN DAMME P,LINDBLAD N,et al.An openlabel,randomized,multicenter study of the safety,tolerability,and immunogenicity of quadrivalent human papillomavirus(types6/11/16/18)vaccine given concomitantly with diphtheria,tetanus,pertussis,and poliomyelitis vaccine in healthy adolescents11 to 17 years of age[J].Pediatr Infect Dis J,2010,29(4):314-318.
• [34]REISINGER K,BLOCK S,COLLINS-OGLE M,et al.Safety,tolerability,and immunogenicity of gardasil given concomitantly with Menactra and Adacel[J].Pediatrics,2010,125(6):1142-1151.
• [35]MCNEIL S,NOYA F,DIONNE M,et al.Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis(Tdap)vaccine and trivalent inactivated influenza vaccine in adults[J].Vaccine,2007,25(17):3464-3474.
• [36]KWON H,HAN S,KIM B,et al.Assessment of safety and efficacy against Bordetella pertussis of a new tetanus-reduced dose diphtheria-acellular pertussis vaccine in a murine model[J].BMC Infect Dis,2017,17(1):247.
• [37]LEROUX-ROELS G,LATTANZI M,SOLIS C,et al.A phase I,randomized,controlled,dose-ranging study of investigational acellular pertussis(aP)and reduced tetanus-diphtheria-acellular pertussis(TdaP)booster vaccines in adults[J].Hum Vaccin Immunother,2018,14(1):45-58.
• [38]SKOFF T,MARTIN S.Impact of tetanus toxoid,reduced diphtheria toxoid,and acellular pertussis vaccinations on reported pertussis cases among those 11 to 18 years of age in an era of waning pertussis immunity:a follow-up analysis[J].JAMA Pediatrics,2016,170(5):453-458.
• [39]GRIFFIN J,LENNEX Y,DONNA W,et al.Pertussis immunisation in pregnancy safety(PIPS)study:a retrospective cohort study of safety outcomes in pregnant women vaccinated with Tdap vaccine[J].Vaccine,2018,36(34):5173-5179.
• [40]DYDA A,MCINTYRE P,KARKI S,et al.Pertussis vaccination in a cohort of older Australian adults following a cocooning vaccination program[J].Vaccine,2018,36(29):4157-4160.
• [41]HALPERIN S,LANGLEY J,YE L,et al.A randomized controlled trial of the safety and immunogenicity of tetanus,diphtheria,and acellular pertussis vaccine immunization during pregnancy and subsequent infant immune response[J].Clin Infect Dis,2018,67(7):1063-1071.
• [42]WANLAPAKORN N,MAERTENS K,CHAITHONGWONGW-ATTHANA S,et al.Assessing the reactogenicity of Tdap vaccine administered during pregnancy and antibodies to Bordetella pertussis antigens in maternal and cord sera of Thai women[J].Vaccine,2018,36(11):1453-1459.
• [43]MORO P,CRAGAN J,TEPPER N,et al.Enhanced surveillance of tetanus toxoid,reduced diphtheria toxoid,and acellular pertussis(Tdap)vaccines in pregnancy in the Vaccine Adverse Event Reporting System(VAERS),2011-2015[J].Vaccine,2016,34(20):2349-2353.
• [44]HUYGEN K,CABORE R,MAERTENS K,et al.Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women[J].Vaccine,2015,33(33):4117-4123.
• [45]DESILVA M,VAZQUEZ-BENITEZ G,NORDIN J D,et al.Maternal Tdap vaccination and risk of infant morbidity[J].Vaccine,2017,35(29):3655-3660.
• [46]FALLO A,NEYRO S,MANONELLES G,et al.Prevalence of pertussis antibodies in maternal blood,cord serum,and infants from mothers with and those without Tdap booster vaccination during pregnancy in Argentina[J].J Pediatr Infect Dis Soci,2018,7(1):11-17.
• [47]MUNOZ F,BOND N,MACCATO M,et al.Safety and immunogenicity of tetanus diphtheria and acellular pertussis(Tdap)immunization during pregnancy in mothers and infants:a randomized clinical trial[J].JAMA,2014,311(17):1760-1769.
• [48]ABU RAYA B,SRUGO I,KESSEL A,et al.The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination[J].Vaccine,2014,32(43):5632-5637.
• [49]GRABMEIER-PFISTERSHAMMER K,HERKNER H,TOUZ-EAU-ROEMER V,et al.Low tetanus,diphtheria and acellular pertussis(Tdap)vaccination coverage among HIV infected individuals in Austria[J].Vaccine,2015,33(32):3929-3932.
• [50]SRIVASTAV A,BLACK C,LU P,et al.Tdap vaccination among healthcare personnel,internet panel survey,2012-2014[J].Am J Prevent Med,2017,53(4):537-546.
• [51]SMALL T,ZELENETZ A,NOY A,et al.Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine(Tdap)after autologous peripheral blood stem cell transplantation[J].Biol Blood Marrow Transplant,2009,15(12):1538-1542.
• [52]HOSHI S,SEPOSO X,OKUBO I,et al.Cost-effectiveness analysis of pertussis vaccination during pregnancy in Japan[J].Vaccine,2018,36(34):5133-5140.
• [53]MCGARRY L,KRISHNARAJAH G,HILL G,et al.Costeffectiveness of Tdap vaccination of adults aged≥65 years in the prevention of pertussis in the US:a dynamic model of disease transmission[J].PloS One,2014,9(1):e72723.
• [54]KULKARNI H,LENZO N,MCLEAN-TOOKE A.Causality of rhabdomyolysis and combined tetanus,diphtheria and acellular pertussis(Tdap)vaccine administration[J].J Clin Pharmacol,2013,53(10):1099-1102.
• [55]COHEN P.Combined reduced-antigen content tetanus,diphtheria,and acellular pertussis(tdap)vaccine-related erythema nodosum:case report and review of vaccine-associated erythema nodosum[J].Dermatol Ther,2013,3(2):191-197.
• [56]CABRERA-MAQUEDA J,HERNANDEZ-CLARES R,BAID-EZ-GUERRERO A,et al.Optic neuritis in pregnancy after Tdap vaccination:Report of two cases[J].Clin Neurol Neurosurg,2017,160:116-118.
• [57]HUANG H,ZHU T,GAO C,et al.Epidemiological features of pertussis resurgence based on community populations with high vaccination coverage in China[J].Epidemiol Infect,2015,143(9):1950-1956.
• [58]ZHANG Q,ZHENG H,LIU M,et al.The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China:a cross sectional study[J].BMC Infect Dis,2012,12(1):138.
• [59]ZHU F,ZHANG S,HOU Q,et al.Booster vaccination against pertussis in Chinese children at six years of age using reduced antigen content diphtheria-tetanus-acellular pertussis vaccine(Boostrix)[J].Hum Vaccin,2010,6(3):263-269.